Peter M Wehmeier

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia
    Peter M Wehmeier
    Lilly Deutschland GmbH, Medical Department, Saalburgstrasse 153, 61350 Bad Homburg, Germany
    Prog Neuropsychopharmacol Biol Psychiatry 31:703-12. 2007
  2. doi Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life
    Peter M Wehmeier
    Lilly Deutschland, Medical Department, Bad Homburg, Germany
    J Adolesc Health 46:209-17. 2010
  3. doi Minor differences in ADHD-related difficulties between boys and girls treated with atomoxetine for attention-deficit/hyperactivity disorder
    Peter M Wehmeier
    Lilly Deutschland GmbH, Medical Department, Bad Homburg, Germany
    Atten Defic Hyperact Disord 2:73-85. 2010
  4. pmc Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years
    Peter M Wehmeier
    Medical Department, Lilly Deutschland GmbH, Bad Homburg, Germany
    Child Adolesc Psychiatry Ment Health 3:3. 2009
  5. pmc Morning and evening behavior in children and adolescents treated with atomoxetine once daily for Attention-Deficit/Hyperactivity Disorder (ADHD): Findings from two 24-week, open-label studies
    Peter M Wehmeier
    Lilly Deutschland, Medical Department, Bad Homburg, Germany
    Child Adolesc Psychiatry Ment Health 3:5. 2009
  6. ncbi Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia
    Peter M Wehmeier
    Medical Department, Child and Adolescent Psychiatry, Lilly Deutschland, Saalburgstr 153, 61350 Bad Homburg, Germany
    J Psychiatr Res 42:676-83. 2008
  7. ncbi Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia
    Peter M Wehmeier
    Medical Department, Lilly Deutschland GmbH, Saalburgstr 153, 61350 Bad Homburg, Germany
    Schizophr Res 91:178-86. 2007
  8. pmc Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials
    Peter M Wehmeier
    Lilly Deutschland GmbH, Medical Department, Bad Homburg, Germany
    Child Adolesc Psychiatry Ment Health 4:30. 2010
  9. doi Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder
    Peter M Wehmeier
    Medical Department, Lilly Deutschland GmbH, Werner Reimers Strasse 2 4, Bad Homburg, Germany
    Qual Life Res 20:691-702. 2011
  10. doi Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study
    Peter M Wehmeier
    Medical Department, Lilly Deutschland GmbH, Saalburgstrasse 153, Bad Homburg, Germany
    J Child Adolesc Psychopharmacol 17:813-30. 2007

Detail Information

Publications21

  1. ncbi Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia
    Peter M Wehmeier
    Lilly Deutschland GmbH, Medical Department, Saalburgstrasse 153, 61350 Bad Homburg, Germany
    Prog Neuropsychopharmacol Biol Psychiatry 31:703-12. 2007
    ..To assess the Quality of Life (QOL) in outpatients with schizophrenia under antipsychotics from two perspectives: a "subjective" perspective as rated by the patient and an "objective" perspective as rated by the physician...
  2. doi Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life
    Peter M Wehmeier
    Lilly Deutschland, Medical Department, Bad Homburg, Germany
    J Adolesc Health 46:209-17. 2010
    ..A model of three categories into which the emotional difficulties fall, and how they impair quality of life, is also presented...
  3. doi Minor differences in ADHD-related difficulties between boys and girls treated with atomoxetine for attention-deficit/hyperactivity disorder
    Peter M Wehmeier
    Lilly Deutschland GmbH, Medical Department, Bad Homburg, Germany
    Atten Defic Hyperact Disord 2:73-85. 2010
    ..However, improvement did not differ significantly between boys and girls. Trial Registration: ClinicalTrials.gov Identifiers NCT00191516 and NCT00191737...
  4. pmc Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years
    Peter M Wehmeier
    Medical Department, Lilly Deutschland GmbH, Bad Homburg, Germany
    Child Adolesc Psychiatry Ment Health 3:3. 2009
    ..The study is limited by the difficulty of obtaining consistent data on the direct cost of treatment for both physical and psychiatric disorders in Germany...
  5. pmc Morning and evening behavior in children and adolescents treated with atomoxetine once daily for Attention-Deficit/Hyperactivity Disorder (ADHD): Findings from two 24-week, open-label studies
    Peter M Wehmeier
    Lilly Deutschland, Medical Department, Bad Homburg, Germany
    Child Adolesc Psychiatry Ment Health 3:5. 2009
    ..CONCLUSION: These findings from two open-label studies suggest that morning and evening behavior and ADHD-related difficulties in the mornings and evenings improve over time with once daily atomoxetine treatment...
  6. ncbi Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia
    Peter M Wehmeier
    Medical Department, Child and Adolescent Psychiatry, Lilly Deutschland, Saalburgstr 153, 61350 Bad Homburg, Germany
    J Psychiatr Res 42:676-83. 2008
    ..These findings suggest that various factors may predict whether a patient with schizophrenia experiences a continuously high QoL, a continuously moderate QoL, a continuously low QoL, or improving QoL whilst on antipsychotic treatment...
  7. ncbi Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia
    Peter M Wehmeier
    Medical Department, Lilly Deutschland GmbH, Saalburgstr 153, 61350 Bad Homburg, Germany
    Schizophr Res 91:178-86. 2007
    ..64; 95% CI 0.42 - 0.96). The combination of several factors predicted concordant ratings, including male sex, young age, high CGI at baseline, and psychotherapy prior to the study...
  8. pmc Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials
    Peter M Wehmeier
    Lilly Deutschland GmbH, Medical Department, Bad Homburg, Germany
    Child Adolesc Psychiatry Ment Health 4:30. 2010
    ..To explore the influence of age on treatment responses to atomoxetine and to assess the relationship between core symptoms of attention deficit/hyperactivity disorder (ADHD) and health-related quality of life (HR-QoL) outcomes...
  9. doi Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder
    Peter M Wehmeier
    Medical Department, Lilly Deutschland GmbH, Werner Reimers Strasse 2 4, Bad Homburg, Germany
    Qual Life Res 20:691-702. 2011
    ..To evaluate the effect of atomoxetine on quality of life (QoL) and family burden in children and adolescents with attention deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant (ODD) or conduct disorder (CD)...
  10. doi Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study
    Peter M Wehmeier
    Medical Department, Lilly Deutschland GmbH, Saalburgstrasse 153, Bad Homburg, Germany
    J Child Adolesc Psychopharmacol 17:813-30. 2007
    ..The degree of perceived difficulties was taken to reflect the health-related quality of life of patients in the study. A second objective was to assess the effectiveness of atomoxetine in children with ADHD in an open-label setting...
  11. pmc Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials
    Alexander Schacht
    Lilly Deutschland, Global Statistical Sciences, Werner Reimers Str 2 4, 61350, Bad Homburg, Germany
    Atten Defic Hyperact Disord 3:335-49. 2011
    ..The results support that the CHIP-CE scale is psychometrically robust over time in terms of internal consistency and structure...
  12. doi Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder
    Mark E Bangs
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pediatrics 121:e314-20. 2008
    ..In this study we examined the effectiveness of atomoxetine for the treatment of oppositional defiant disorder comorbid with attention-deficit/hyperactivity disorder...
  13. ncbi Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials
    Rodrigo Escobar
    Lilly S A, Alcobendas, Spain
    J Clin Psychopharmacol 30:145-51. 2010
    ..These findings suggest that measuring quality of life adds clinically relevant insight beyond core symptom evaluation in children and adolescents with ADHD...
  14. doi Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study
    Ralf W Dittmann
    Medical Department, Child and Adolescent Psychiatry, Lilly Deutschland GmbH, Saalburgstrasse 153, Bad Homburg, Germany
    J Child Adolesc Psychopharmacol 18:54-69. 2008
    ..The aim of this study was to assess effectiveness and tolerability of oral olanzapine treatment of adolescents with schizophrenic disorders...
  15. ncbi Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study
    Michael Kluge
    Max Planck Institute of Psychiatry, Kraepelinstrasse 2 10, Munich, Germany
    J Clin Psychopharmacol 27:662-6. 2007
    ..These results suggest that both clozapine and olanzapine can induce food craving and binge eating, however, olanzapine possibly to a greater extent. Findings on clinical efficacy and safety are in accordance with previous reports...
  16. ncbi Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation
    Peter M Wehmeier
    Department of Child and Adolescent Psychiatry, Philipps University, Hans Sachs Str 4 8, 35033 Marburg, Germany
    Psychiatry Res 133:273-6. 2005
    ..2 kg and finally had a weight of 100.4 kg (BMI=33.8 kg/m2). Because both patients experienced considerable weight gain during treatment, our observation suggests that the antipsychotic-induced weight gain is under strong genetic control...
  17. ncbi Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine
    Peter M Wehmeier
    Department of Child and Adolescent Psychiatry, Philipps University of Marburg, Hans Sachs Strasse 4 8, 35033 Marburg, Germany
    J Child Adolesc Psychopharmacol 14:267-71. 2004
    ..With the exception of the case which prompted our study, none of the patients were found to have developed any such disorder in the course of further treatment with clozapine...
  18. ncbi Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs
    Frank M Theisen
    Clinical Research Group, Department of Child and Adolescent Psychiatry, University of Marburg, Hans Sachs Str 6, D 35039 Marburg, Germany
    Psychiatr Genet 15:285-9. 2005
    ..An important caveat is that, owing to the sample size, the heritability estimates have a large standard error and thus have to be interpreted with caution...
  19. ncbi Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine
    Peter M Wehmeier
    J Clin Psychopharmacol 23:102-3. 2003